Bicara Therapeutics (NASDAQ:BCAX) Shares Up 6.7% - Time to Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) rose 6.7% during trading on Tuesday . The company traded as high as $12.00 and last traded at $12.25. Approximately 44,477 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 582,318 shares. The stock had previously closed at $11.48.

Wall Street Analyst Weigh In

BCAX has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright dropped their price objective on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Wall Street Zen cut Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective on the stock in a research report on Friday, May 23rd. Finally, Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Price Performance

The firm has a 50 day moving average price of $12.40 and a 200 day moving average price of $13.90.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $25,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $33,000. Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $35,000. Finally, CWM LLC purchased a new stake in shares of Bicara Therapeutics during the first quarter worth about $29,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.